This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To assess the effects of ALA as a disease‐modifying agent in DPN, looking at clinical indicators and biomarkers of disease (symptoms, neuropathy scores, ulceration, quality of life, and neurophysiological parameters), and adverse events.